Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.
GlobeNewswire
· SIMLANDI is the first interchangeable high-concentration, citrate-free biosimilar to Humira^®REYKJAVIK, Iceland and PARSIPPANY,..
· SIMLANDI is the first interchangeable high-concentration, citrate-free biosimilar to Humira^®REYKJAVIK, Iceland and PARSIPPANY,..
The Americas, holding a dominant 40.97% market share, are expected to grow at a notable CAGR of 6.47% during the forecast period...
The dynamics of the myasthenia gravis market are anticipated to change in the coming years owing to the improvement in the..